Schering-Plough has appointed the executive team members of the company’s global animal health unit: Intervet / Schering- Plough Animal Health.
These appointments define the major steps in the design process of the animal
health unit. The executive team is chaired by Ruurd Stolp, senior vice president
and president animal health. Dr Stolp reports to Fred Hassan, chairman and CEO,
Schering-Plough.
Appointed as executive team members are:
* Raul
Kohan, senior vice president, corporate excellence and deputy head animal
health
* Hugo Wahnish, vice president, global AH regions
* René
Aerts, vice president, animal health, research and development
biologicals
* K.J. Varma, vice president, AH, R&D
pharmaceuticals
* Jochen Bader, vice president, global finance, animal
health
* Malte Greune, vice president global supply chain animal
health
* Mark van Heumen, law lead global animal health
*
Andreas König, quality head, global quality operations, animal
health
* Gráinne Higgins, vice president, HR, animal health
The
new combination Intervet / Schering-Plough Animal Health strengthens the animal
health portfolio in several areas and brings together complementary lines of
pharmaceuticals, biologicals and innovative services.
Intervet /
Schering-Plough Animal Health is not only the world market leader in the
production of animal health vaccines, but is also one of the world’s leaders in
the field of animal health—with offices in more than 50 countries and products
marketed in over 120 countries.
Schering-Plough completed its acquisition
of Intervet last November. The American company purchased the animal health
division from Dutch chemical giant Akzo Nobel for €11 billion.
Related
websites:
Intervet
Schering-Plough